Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 69,637,680
  • Shares Outstanding, K 2,072,550
  • Annual Sales, $ 37,725 M
  • Annual Income, $ 6,130 M
  • EBIT $ 4,926 M
  • EBITDA $ 7,779 M
  • 60-Month Beta 0.64
  • Price/Sales 1.84
  • Price/Cash Flow 6.45
  • Price/Book 3.96

Options Overview Details

View History
  • Implied Volatility 25.21% ( +1.60%)
  • Historical Volatility 23.22%
  • IV Percentile 75%
  • IV Rank 48.84%
  • IV High 46.75% on 10/09/24
  • IV Low 4.64% on 08/29/24
  • Put/Call Vol Ratio 0.19
  • Today's Volume 8,929
  • Volume Avg (30-Day) 3,942
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 131,300
  • Open Int (30-Day) 120,133

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.54
  • Number of Estimates 4
  • High Estimate 0.63
  • Low Estimate 0.49
  • Prior Year 0.72
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.04 +1.69%
on 12/20/24
36.28 -7.40%
on 12/09/24
+0.25 (+0.75%)
since 11/20/24
3-Month
32.83 +2.36%
on 11/15/24
41.80 -19.62%
on 10/09/24
-7.20 (-17.65%)
since 09/20/24
52-Week
32.83 +2.36%
on 11/15/24
45.92 -26.84%
on 05/15/24
-2.59 (-7.16%)
since 12/20/23

Most Recent Stories

More News
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have gained 15.4% in a year against the industry’s decline of 10.8%. The stock has...

MRK : 98.05 (-1.48%)
GILD : 92.57 (+1.62%)
GSK : 33.60 (+0.51%)
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
NVS : 97.11 (+0.35%)
ONC.TO : 1.19 (-9.16%)
PFE : 26.36 (+2.29%)
GSK : 33.60 (+0.51%)
BMY : 57.33 (+1.83%)
Top Research Reports for Netflix, BP & Constellation Energy

Wednesday, December 11, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix, Inc....

NFLX : 909.05 (+0.78%)
TSLA : 421.06 (-3.46%)
CEG : 227.02 (+0.82%)
TRV : 240.76 (+1.28%)
GSK : 33.60 (+0.51%)
BP : 28.60 (+0.67%)
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?

GSK GSK stock has declined 20.2% in the past three months compared with a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below....

HLN : 9.69 (-0.10%)
MRNA : 39.39 (-0.43%)
GSK : 33.60 (+0.51%)
SNY : 47.71 (+0.44%)
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD) treatment for...

ALNY : 245.44 (+2.75%)
GILD : 92.57 (+1.62%)
GSK : 33.60 (+0.51%)
PFE : 26.36 (+2.29%)
Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?

Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It...

MRK : 98.05 (-1.48%)
GILD : 92.57 (+1.62%)
GSK : 33.60 (+0.51%)
Vaccine Stocks Slide, Psychedelic Stocks Surge After RFK Jr. HHS Nomination

Markets sent a clear message Friday following President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services (HHS). Vaccine stocks took a nosedive,...

CMPS : 3.97 (+1.28%)
PSIL : 10.62 (+1.15%)
ATAI : 1.1900 (unch)
AZN : 65.35 (+1.41%)
BVNRY : 8.9600 (+1.36%)
NVAX : 8.70 (+0.23%)
MRNA : 39.39 (-0.43%)
CYBN : 9.61 (+3.11%)
GSK : 33.60 (+0.51%)
PFE : 26.36 (+2.29%)
BNTX : 113.08 (+1.56%)
SNY : 47.71 (+0.44%)
Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per share,...

MRK : 98.05 (-1.48%)
MRNA : 39.39 (-0.43%)
GSK : 33.60 (+0.51%)
PFE : 26.36 (+2.29%)
Gilead, MRK Report Data From Investigational Combination Study for HIV

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV.Data showed...

MRK : 98.05 (-1.48%)
ALNY : 245.44 (+2.75%)
GILD : 92.57 (+1.62%)
GSK : 33.60 (+0.51%)
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale

Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in its consumer healthcare (CHC)...

JNJ : 144.47 (+0.62%)
GSK : 33.60 (+0.51%)
PFE : 26.36 (+2.29%)
SNY : 47.71 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 34.80
2nd Resistance Point 34.33
1st Resistance Point 33.97
Last Price 33.60
1st Support Level 33.14
2nd Support Level 32.67
3rd Support Level 32.31

See More

52-Week High 45.92
Fibonacci 61.8% 40.92
Fibonacci 50% 39.38
Fibonacci 38.2% 37.83
Last Price 33.60
52-Week Low 32.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar